DUOPHARMA BIOTECH BERHAD

KLSE: 7148 (DPHARMA)

最近更新时间: 1小时之前

1.48

0.02 (1.37%)

  • 1天 1.37%
  • 5天 0.68%
  • 1月 7.25%
  • 6月 8.03%
  • 今年至今天 19.35%
  • 1年 23.33%
  • 5年 -27.70%
前收盘价格 1.46
收盘价格 1.46
成交量 797,900
平均成交量 (3个月) 749,620
市值 1,423,674,880
市盈率 (P/E TTM) 16.44
预期市盈率 (P/E Forward) 14.24
价格/销量 (P/S) 1.56
股市价格/股市净资产 (P/B) 1.89
52周波幅
1.07 (-27%) — 1.57 (6%)
利润日期 13 Aug 2025 - 18 Aug 2025
股息率 (DY TTM) 3.07%
营业毛利率 8.26%
营业利益率 (TTM) 14.69%
稀释每股收益 (EPS TTM) 0.080
季度收入增长率 (YOY) 36.20%
季度盈利增长率 (YOY) 67.80%
总债务/股东权益 (D/E MRQ) 70.73%
流动比率 (MRQ) 3.83
营业现金流 (OCF TTM) 114.27 M
杠杆自由现金流 (LFCF TTM) 53.91 M
资产报酬率 (ROA TTM) 5.22%
股东权益报酬率 (ROE TTM) 10.48%

市场趋势

短期 中期
行业 Drug Manufacturers - Specialty & Generic (MY) 混合的 混合的
Drug Manufacturers - Specialty & Generic (全球的) 混合的 混合的
股票 DPHARMA 看涨 看涨

AIStockmoo 评分

0.2
分析师共识 3.0
内部交易活动 -3.5
价格波动 -5.0
技术平均移动指标 2.5
技术振荡指标 4.0
平均 0.20

相关股票

股票 市值 DY P/E（TTM） P/B
DPHARMA 1 B 3.07% 16.44 1.89
RHONEMA 157 M 3.55% 17.63 0.870
PLABS 72 M - 26.00 0.950

Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
部门 Healthcare
行业 Drug Manufacturers - Specialty & Generic
投资方式 Small Value
内部持股比例 2.64%
机构持股比例 71.87%

所有权

姓名 日期 持有股份
Billion Victory Sdn Bhd 31 Mar 2023 15,070,000 (1.57%)
Manulife Investment Shariah Progress Fund 31 Oct 2022 8,670,000 (0.90%)
52周波幅
1.07 (-27%) — 1.57 (6%)
目标价格波幅
1.65 (11%) — 1.72 (16%)
高 1.72 (TA, 16.22%) 购买
中 1.69 (14.19%)
低 1.65 (RHB, 11.49%) 购买
平均值 1.69 (14.19%)
总计 2 购买
平均价格@调整类型 1.52
公司 日期 目标价格 调整类型 价格@调整类型
TA 27 Feb 2026 1.72 (16.22%) 购买 1.49
19 Feb 2026 1.72 (16.22%) 购买 1.55
RHB 19 Feb 2026 1.65 (11.49%) 购买 1.55
名称 平均购买 ($) 平均卖出 ($) 总净额 总净值 ($)
EMPLOYEES PROVIDENT FUND BOARD - 1.49 -939,100 -1,405,041
LEMBAGA TABUNG HAJI - - 0 0
累积净数量 -939,100
累积净值 ($) -1,405,041
累积平均购买 ($) -
累积平均卖出 ($) 1.49
名称 持有人 日期 类型 数量 价格 价值 ($)
LEMBAGA TABUNG HAJI 大股东 02 Mar 2026 利益通知 500,000 - -
EMPLOYEES PROVIDENT FUND BOARD 大股东 26 Feb 2026 处理 (-) 200,000 1.47 294,000
EMPLOYEES PROVIDENT FUND BOARD 大股东 23 Feb 2026 处理 (-) 500,000 1.50 750,000
EMPLOYEES PROVIDENT FUND BOARD 大股东 20 Feb 2026 处理 (-) 239,100 1.51 361,041
  • 3M
日期 类型 细节
04 Mar 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - LEMBAGA TABUNG HAJI
04 Mar 2026 TheEdge Contractors, material firms face cost pressures amid Middle East conflict, CIMB Securities flags
04 Mar 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
03 Mar 2026 TheEdge Tabung Haji emerges as substantial shareholder in Duopharma
03 Mar 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
03 Mar 2026 公告 Notice of Interest Sub. S-hldr (Section 137 of CA 2016) - LEMBAGA TABUNG HAJI
02 Mar 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
27 Feb 2026 公告 DPHARMA - Notice of Book Closure
27 Feb 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
26 Feb 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
26 Feb 2026 公告 Duopharma Biotech maintains robust revenue and profit growth momentum
26 Feb 2026 公告 Second Interim Dividend
26 Feb 2026 公告 Quarterly rpt on consolidated results for the financial period ended 31/12/2025
26 Feb 2026 公告 MATERIAL LITIGATION
26 Feb 2026 TheEdge Duopharma logs record full-year net profit of RM87.5 mil on resilient demand
26 Feb 2026 TheEdge Duopharma logs record annual profit of RM87.5 mil on resilient demand
25 Feb 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
20 Feb 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
19 Feb 2026 TheEdge Duopharma hits three-year high after MOH contract wins for insulin products
19 Feb 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
16 Feb 2026 公告 ACCEPTANCE OF TENDER OFFER (HEREINAFTER REFERRED TO AS THE "LETTER OF AWARD" OR "LOA") FOR THE SUPPLY OF RECOMBINANT HUMAN INSULIN FORMULATIONS (HEREINAFTER REFERRED TO AS THE "PRODUCTS") TO THE GOVERNMENT OF MALAYSIA
16 Feb 2026 TheEdge Duopharma, IGB, MISC, Seal, GDB, Johan Holdings & Farmiera
16 Feb 2026 TheEdge Ministry of Health awards RM65.08 mil contract to Duopharma for distribution of insulin
16 Feb 2026 公告 ACCEPTANCE OF TENDER OFFER (HEREINAFTER REFERRED TO AS THE "LETTER OF AWARD" OR "LOA") FOR THE SUPPLY OF INSULIN INJECTION (HEREINAFTER REFERRED TO AS THE "PRODUCT") BY DUOPHARMA (M) SENDIRIAN BERHAD (A WHOLLY-OWNED SUBSIDIARY OF DUOPHARMA BIOTECH BERHAD) TO THE MINISTRY OF HEALTH'S FACILITIES
13 Feb 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
11 Feb 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
05 Feb 2026 公告 MATERIAL LITIGATION
03 Feb 2026 公告 MATERIAL LITIGATION
03 Feb 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
02 Feb 2026 TheEdge Watching for winners and losers of stronger ringgit in corporate earnings
29 Jan 2026 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
15 Jan 2026 TheEdge Cover Story: Stock picks for 2026 - Navigating opportunities and risks
22 Dec 2025 公告 MATERIAL LITIGATION
10 Dec 2025 TheEdge Local pharma leap needs government support, says Duopharma’s outgoing chief
显示更多
股息率 (DY TTM) 3.07%
5年平均股息收益率 2.43%
股息支付比率 39.53%
预计下次股息支付 Sep 2026
除息日 公告日期 支付日期 详情
12 Mar 2026 26 Feb 2026 30 Mar 2026 0.0305 现金
08 Sep 2025 21 Aug 2025 24 Sep 2025 0.015 现金
05 Mar 2025 19 Feb 2025 19 Mar 2025 0.02 现金
29 Aug 2024 15 Aug 2024 12 Sep 2024 0.01 现金
07 Mar 2024 22 Feb 2024 21 Mar 2024 0.018 现金
08 Sep 2023 24 Aug 2023 22 Sep 2023 0.005 现金
07 Apr 2023 27 Mar 2023 09 May 2023 0.018 现金
29 Aug 2022 16 Aug 2022 14 Sep 2022 0.005 现金
14 Apr 2022 24 Mar 2022 13 May 2022 0.018 现金
30 Aug 2021 17 Aug 2021 15 Sep 2021 0.005 现金
21 Apr 2021 08 Apr 2021 21 May 2021 0.06 现金
28 Aug 2020 13 Aug 2020 11 Sep 2020 0.005 现金
13 Jul 2020 30 Jun 2020 12 Aug 2020 0.05 现金
15 Oct 2019 02 Oct 2019 14 Nov 2019 0.01 现金
26 Jun 2019 13 Jun 2019 26 Jul 2019 0.04 现金
02 Nov 2018 22 Oct 2018 23 Nov 2018 0.015 现金
13 Jun 2018 31 May 2018 17 Jul 2018 0.06 现金
17 Oct 2017 25 Aug 2017 10 Nov 2017 0.025 现金
26 May 2017 24 Feb 2017 23 Jun 2017 0.04 现金
19 Oct 2016 22 Aug 2016 11 Nov 2016 0.025 现金
06 Jun 2016 23 Feb 2016 28 Jun 2016 0.055 现金
13 Oct 2015 25 Aug 2015 06 Nov 2015 0.04 现金
27 May 2015 24 Feb 2015 25 Jun 2015 0.145 现金
15 Oct 2014 26 Aug 2014 07 Nov 2014 0.04 现金
22 May 2014 26 Feb 2014 20 Jun 2014 0.135 现金
14 Oct 2013 28 Aug 2013 08 Nov 2013 0.04 现金
14 Jun 2013 22 Mar 2013 12 Jul 2013 0.105 现金
15 Oct 2012 16 Aug 2012 09 Nov 2012 0.035 现金
06 Jun 2012 16 Mar 2012 29 Jun 2012 0.145 现金
05 Oct 2011 18 Aug 2011 28 Oct 2011 0.035 现金
08 Jun 2011 21 Apr 2011 27 Jun 2011 0.11 现金
06 Oct 2010 02 Sep 2010 28 Oct 2010 0.045 现金
09 Jun 2010 21 Apr 2010 25 Jun 2010 0.12 现金
01 Oct 2009 26 Aug 2009 23 Oct 2009 0.06 现金
10 Jun 2009 15 Apr 2009 26 Jun 2009 0.07 现金
08 Oct 2008 26 Aug 2008 28 Oct 2008 Interim Dividend
03 Oct 2007 24 Aug 2007 18 Oct 2007 Interim Dividend
29 May 2007 25 Apr 2007 08 Jun 2007 Final Dividend
11 Sep 2006 23 Aug 2006 22 Sep 2006 Interim Dividend
18 May 2006 24 Apr 2006 08 Jun 2006 First and Final Dividend
26 Jul 2005 06 Jun 2005 18 Aug 2005 Final Dividend
21 Oct 2004 06 Oct 2004 08 Nov 2004 Interim Dividend
06 Jul 2004 01 Jun 2004 28 Jul 2004 Final Dividend
26 Sep 2003 09 Sep 2003 20 Oct 2003 Interim Dividend
23 Jun 2003 25 Apr 2003 08 Jul 2003 First and Final Dividend
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2026 0.031 1 2.06
2025 0.035 2 2.80
2024 0.028 2 2.24
2023 0.023 2 1.83
2022 0.023 2 1.43
2021 0.065 2 3.87
2020 0.055 2 2.17
2019 0.050 2 4.70
2018 0.075 2 10.53
2017 0.065 2 7.99
2016 0.080 2 12.57
2015 0.185 2 21.97
2014 0.175 2 29.38
2013 0.145 2 23.59
2012 0.180 2 35.47
2011 0.145 2 30.13
2010 0.165 2 28.97
2009 0.130 2 23.22
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票